Insufficient scRNA-seq data for expression of SGO2 at single-cell level.
Insufficient scRNA-seq data for expression of SGO2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 99% | 184.85 | 455 / 459 | 96% | 8.37 | 1076 / 1118 |
uterus | 98% | 134.69 | 167 / 170 | 97% | 10.51 | 445 / 459 |
esophagus | 95% | 202.80 | 1367 / 1445 | 99% | 10.31 | 182 / 183 |
ovary | 99% | 190.34 | 178 / 180 | 94% | 6.03 | 406 / 430 |
intestine | 97% | 193.50 | 938 / 966 | 93% | 7.41 | 491 / 527 |
bladder | 95% | 124.52 | 20 / 21 | 91% | 6.71 | 457 / 504 |
stomach | 92% | 140.81 | 332 / 359 | 93% | 7.79 | 265 / 286 |
lung | 91% | 162.28 | 528 / 578 | 92% | 7.27 | 1064 / 1155 |
skin | 98% | 766.79 | 1768 / 1809 | 79% | 7.07 | 371 / 472 |
brain | 95% | 108.13 | 2517 / 2642 | 71% | 4.35 | 501 / 705 |
prostate | 94% | 104.04 | 230 / 245 | 49% | 1.70 | 244 / 502 |
pancreas | 69% | 50.95 | 225 / 328 | 69% | 2.89 | 123 / 178 |
thymus | 98% | 118.85 | 640 / 653 | 29% | 2.26 | 173 / 605 |
adrenal gland | 95% | 146.65 | 244 / 258 | 24% | 1.10 | 55 / 230 |
kidney | 73% | 73.19 | 65 / 89 | 38% | 1.24 | 341 / 901 |
lymph node | 0% | 0 | 0 / 0 | 100% | 10.78 | 29 / 29 |
spleen | 100% | 273.27 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 11.11 | 45 / 45 |
adipose | 100% | 421.62 | 1199 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 91% | 98.40 | 1214 / 1335 | 0% | 0 | 0 / 0 |
heart | 81% | 78.90 | 697 / 861 | 0% | 0 | 0 / 0 |
liver | 35% | 32.04 | 80 / 226 | 41% | 1.87 | 166 / 406 |
peripheral blood | 61% | 706.29 | 571 / 929 | 0% | 0 | 0 / 0 |
muscle | 52% | 37.12 | 414 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 5% | 0.12 | 4 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051321 | Biological process | meiotic cell cycle |
GO_0051301 | Biological process | cell division |
GO_0007059 | Biological process | chromosome segregation |
GO_0051177 | Biological process | meiotic sister chromatid cohesion |
GO_0000775 | Cellular component | chromosome, centromeric region |
GO_0000776 | Cellular component | kinetochore |
GO_0016604 | Cellular component | nuclear body |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0030892 | Cellular component | mitotic cohesin complex |
GO_0005515 | Molecular function | protein binding |
Gene name | SGO2 |
Protein name | Shugoshin 2 (Shugoshin-2) (Shugoshin-like 2) (Tripin) Shugoshin 2 |
Synonyms | SGOL2 |
Description | FUNCTION: Cooperates with PPP2CA to protect centromeric cohesin from separase-mediated cleavage in oocytes specifically during meiosis I. Has a crucial role in protecting REC8 at centromeres from cleavage by separase. During meiosis, protects centromeric cohesion complexes until metaphase II/anaphase II transition, preventing premature release of meiosis-specific REC8 cohesin complexes from anaphase I centromeres. Is thus essential for an accurate gametogenesis. May act by targeting PPP2CA to centromeres, thus leading to cohesin dephosphorylation (By similarity). Essential for recruiting KIF2C to the inner centromere and for correcting defective kinetochore attachments. Involved in centromeric enrichment of AUKRB in prometaphase. . |
Accessions | C9JW92 ENST00000357799.9 [Q562F6-1] ENST00000409203.3 [Q562F6-3] Q562F6 ENST00000418045.5 |